Telix Pharmaceuticals Limited
ASX: TLX
Surging Illuccix sales and new product launches power Telix’s robust growth.
(Source: TradingView) 3-Month Performance Profile of TLX on a DTF compared to S&P/ASX 200 (XJO).
Telix Pharmaceuticals reported H1 FY25 total revenue of $615.34 million, marking a 69% year-over-year increase, driven by robust U.S. dose volumes and expanding global launches. The
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
